My local compounding pharmacy stopped selling Lipoden, MIC, and other injectables over 6 months ago, instead choosing to move to a model where clients had to come in for on-site injections and were charged and injection fee
NAD+ therapy is shown to support energy, mitochondrial function, cognitive clarity, and cellular repair, especially in adults experiencing fatigue, inflammation, or early signs of age-related decline
If approved on schedule, US patients could access it in early-to-mid 2027
If you experience both sleep disruption and elevated blood pressure, the NO pathway may be involved
As of 2026, injectable GHK-Cu is classified Category 2 by the FDA, restricting it from 503A pharmacy compounding
This makes it a targeted tool for people who want to address stubborn fat without changing other aspects of their physiology